ClinicalTrials.gg
RecruitingNCT07946770Updated Nov 18, 2026

AI-Assisted Diabetes Education for Children With Type 1 Diabetes

An interventional study of AI-Assisted Video-Based Diabetes Education in Type 1 Diabetes Mellitus, sponsored by Yuzuncu Yil University. Recruiting at 1 site in Turkey (Türkiye). Open to participants aged 13 Years to 18 Years. Per ClinicalTrials.gov, last updated 2026-11-18.

Sponsored by Yuzuncu Yil University · Not applicable, Interventional, and Supportive care

From the registry’s dates

  • Registered 8 months after the study started (first participant enrolled Mar 2026, registered Nov 2026).
  • Started Mar 2026; still recruiting 8 months later.
Updated Nov 18, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
13 Years to 18 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 77 studies in Diabetes Mellitus, Type 1 with a site in Turkey — 15 open to participants now, 17 under way, none of them phase 3. Diabetes Mellitus, Type 1 · Turkey.

Planned enrollment
21st of 49
60 · median 58
Started
2026
with 7 others
No phase
39 of 77
12 open now
Primary completion
2027-02
later than 14 of 16 live
Registered
77th of 77
by date

Among the 77 studies in Diabetes Mellitus, Type 1 with a site in Turkey, this one is the 21st largest by planned enrollment of the 49 interventional ones that give a count, is one of 8 that started in 2026, is one of 39 with no phase, reaches primary completion later than 14 of the 16 other live ones, and was the 77th registered.

Diabetes Mellitus, Type 1

3,755 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.

Browse Diabetes Mellitus, Type 1 studies →

Open to participants now

15 of the 77 studies in Diabetes Mellitus, Type 1 with a site in Turkey are open now. Recruiting first, the newest first:

9 more — sign in →

All 15 open studies →

A study can be open while its sites in Turkey have not opened yet or have stopped. Only those recruiting at a site in Turkey →

Who these studies take

Of the 415 Diabetes Mellitus, Type 1 studies recruiting now, 129 (31%) set no upper age limit and 260 (63%) stop at 75 or younger; 187 take children under 18; 65 take healthy volunteers.

This study: 13 Years to 18 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 77 studies in Diabetes Mellitus, Type 1 with a site in Turkey, or all of them as a file.
02

Study summary

This randomized controlled study evaluates the effects of an artificial intelligence-assisted diabetes education video on quality of life, diabetes self-management skills, and glycemic control in children with type 1 diabetes mellitus. Participants are assigned to an intervention group receiving a 12-minute educational video through a Meta Quest 2 virtual reality headset or a control group receiving routine diabetes education and care. Outcomes are assessed at baseline and at three months using validated questionnaires and routinely recorded HbA1c values.

Read the detailed description

This single-center, parallel-group randomized controlled study investigates the effects of artificial intelligence-assisted video-based diabetes education on health-related quality of life, diabetes self-management skills, and glycemic control among children and adolescents diagnosed with type 1 diabetes mellitus.

The study is conducted at the Pediatric Endocrinology Outpatient Clinic of Van Training and Research Hospital in Türkiye. A target sample of 60 participants was determined through an a priori power analysis, allowing for potential attrition. Eligible participants are allocated to an intervention group or a control group using a computer-generated random sequence.

Participants in the intervention group receive a 12-minute diabetes education video developed using artificial intelligence tools and delivered through a Meta Quest 2 virtual reality headset. The video content was prepared using established diabetes management guidelines. Artificial intelligence tools were used to develop the educational script, images, digital avatar, and voice narration. The virtual reality headset is used to support attention to the educational material. Disposable protective eye pads and headset cleaning procedures are used between participants to reduce the risk of cross-contamination.

Participants in the control group continue to receive routine diabetes education and clinical care. Outcomes are evaluated at baseline and three months after the intervention. Diabetes-specific quality of life is assessed using the PedsQL 3.0 Diabetes Module, and diabetes self-management skills are assessed using the Life Management Skills Scale for Children With Diabetes. Glycemic control is evaluated using HbA1c values obtained from routinely collected medical records. No additional blood samples or laboratory tests are requested for research purposes.

03

Conditions studied

  • Type 1 Diabetes Mellitus

Keywords

  • Artificial Intelligence
  • Diabetes Education
  • Virtual Reality
  • Self-Management
  • Quality of Life
  • Glycemic Control
  • Pediatric Nursing
04

Who can participate

Ages eligible
13 Years to 18 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Children and adolescents within the approved study age range.
  • Diagnosis of type 1 diabetes mellitus at least six months before enrollment.
  • Regular attendance at scheduled clinical follow-up visits.
  • Ability to read and write.
  • No communication barriers involving speech, hearing, or vision that would prevent participation.

Exclusion criteria

Exclusion Criteria:

  • Presence of a chronic disease other than type 1 diabetes mellitus.
  • Unavailability of measurements.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    AI-Assisted Diabetes Education

    Participants receive a 12-minute diabetes education video developed with artificial intelligence tools and delivered through a Meta Quest 2 virtual reality headset. The educational material addresses essential aspects of type 1 diabetes management and is based on established diabetes guidelines. The headset is used to support participant attention during the educational session.

    Behavioral: AI-Assisted Video-Based Diabetes Education

  • No intervention
    Routine Diabetes Education and Care

    Participants in the control group continue to receive routine diabetes education, follow-up, and clinical care provided by the pediatric endocrinology outpatient clinic. They do not receive the artificial intelligence-assisted educational video.

Interventions

  • BehavioralAI-Assisted Video-Based Diabetes Education

    Participants in the experimental group receive a 12-minute diabetes education video developed using artificial intelligence tools. The educational content is based on established diabetes management guidelines and covers essential aspects of type 1 diabetes management. The video was prepared using ChatGPT, Gemini, HeyGen, ElevenLabs, and CapCut and is delivered through a Meta Quest 2 virtual reality headset to support attention and engagement. Disposable protective eye pads are used, and the headset is cleaned between participants to reduce the risk of cross-contamination.

06

What researchers measure

Primary outcomes

  1. Diabetes-Specific Quality of Life

    Change in diabetes-specific quality of life from baseline to month 3, assessed using the Pediatric Quality of Life Inventory (PedsQL) 3.0 Diabetes Module. The 28-item instrument is scored on a 0-100 scale, with higher scores indicating better quality of life.

    Time frame: Baseline and Month 3

  2. Diabetes Self-Management Skills

    Change in diabetes self-management skills from baseline to month 3, assessed using the Life Management Skills Scale for Children With Diabetes. The instrument contains 15 items covering diabetes management knowledge and coping skills. Higher scores indicate better life management skills.

    Time frame: Baseline and Month 3

  3. Glycemic Control (HbA1c)

    Change in glycated hemoglobin (HbA1c) percentage from baseline to month 3. HbA1c values are obtained from medical records following routine physician-ordered clinical assessments. No additional laboratory tests are performed specifically for this study.

    Time frame: Baseline and Month 3

07

Study locations

1 of 1 sites recruiting
  • Van Training and Research Hospital
    Van, 65100, Turkey (Türkiye)
    Recruiting
    • Nihat güneş · Contact
08

References and documents

Publications

  • Tinmaz G, Altundag S. The effect of diabetes education given to children with type 1 diabetes mellitus with digital games and video animation on quality of life. J Pediatr Nurs. 2025 Mar-Apr;81:142-154. doi: 10.1016/j.pedn.2025.01.023. Epub 2025 Feb 3. PubMed 39904003 ↗

Individual participant data

Plan to share: No — Individual participant data (IPD) will not be shared with other researchers due to privacy and confidentiality considerations, particularly because the study involves children and adolescents with type 1 diabetes mellitus. Data will be used only for the purposes approved by the ethics committee.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2026 (actual). Primary completion is estimated for Feb 2027, 10 months after the start.

Of 848 non-industry interventional studies with no phase under Diabetes Mellitus, Type 1, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 38. This study's planned 10 months is below that.

Counting every sponsor, half of 953 studies reached it within 18 months; a quarter within 9 and three quarters within 35.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 12, 2026
First posted
Nov 18, 2026
StartActual
Mar 10, 2026
Primary completionEst.
Feb 1, 2027
CompletionEst.
Feb 1, 2027
Last update
Nov 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 18, 2026
Show all 1 update
  1. Nov 18, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07946770
Lead sponsor
Yuzuncu Yil University
Responsible party
Nihat GÜNEŞ (Registered Nurse, Yuzuncu Yil University) — Principal investigator
First posted
Nov 18, 2026
Start date
Mar 10, 2026
Primary completion
Feb 1, 2027 (estimated)
Completion
Feb 1, 2027 (estimated)
Last update
Nov 18, 2026

Study contacts

Nihat Güneş
Contact
nihatgunes2314@gmail.com
05373083143

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion